Regulatory Clearance Covers Full Biological Inputs Portfolio
New Delhi, February 23 BioPrime AgriSolutions on Monday announced that it has received regulatory approval from the Union Ministry of Agriculture for its entire portfolio of biostimulant products, spanning 20 formulations.The approval has been granted by the INM Biostimulant Cell under the ministry and covers both foliar and granular applications. With this clearance, the Pune-based company joins a select group of firms in India that hold regulatory compliance for a broad range of biological agricultural inputs.
The approved formulations include products based on humic and fulvic acids, seaweed, botanicals, and amino acids.
Leadership Calls It a Strategic Milestone
Chief Executive Renuka Diwan described the development as more than a regulatory milestone.“This is much more than just a regulatory win. It is a signal that high-science biological innovations can move from the lab to the field within structured regulatory frameworks,” she said in a statement.
Chief Operating Officer Shekhar Bhosle added that the approval reflects years of focused scientific work and sustained regulatory engagement. He said the milestone underscores the company’s scientific rigor and persistence in navigating compliance requirements.
Focus on Soil Health, Crop Resilience and Commercial Expansion
According to the company, the approved biostimulants are designed to enhance soil health, improve nutrient-use efficiency, and strengthen crop resilience against environmental stress.Following the regulatory clearance, BioPrime AgriSolutions said it will now concentrate on scaling its commercial footprint and strengthening distribution partnerships. At the same time, the company plans to advance its next-generation biologicals pipeline.
The firm noted that demand for science-backed biostimulants is expected to increase as regenerative agriculture continues to gain ground and transitions into mainstream farming practice across India.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.